Axillary Hyperhidrosis Market to Grow Significantly by 2032 | SweatBlock, Certain Dri, Duradry, Zerosweat, Allergan plc., Dermavant Sciences Inc, Botanix Pharmaceuticals Ltd, Dermata Therapeutics Inc, and others.

{Delhi, India} To strategically aid Axillary Hyperhidrosis Companies in developing drugs for Axillary Hyperhidrosis, DelveInsight launched a report titled “Axillary Hyperhidrosis Market Insight Epidemiology and Market Forecast, 2032”. This comprehensive report delves into epidemiology-based market analysis, providing a roadmap for success in the dynamic landscape of the Axillary Hyperhidrosis Market.

Download a free sample copy of the “Axillary Hyperhidrosis Market Report”

Key Takeaways from the Axillary Hyperhidrosis Market Research Report

• The increase in Axillary Hyperhidrosis market size is a direct consequence of the expected approval of emerging therapy and the increasing patient population of Axillary Hyperhidrosis (AH) in the 7MM.
• As per DelveInsight analysts, the total Axillary Hyperhidrosis prevalence population in the US was 10,491,560.
• As per DelveInsight, nearly 1,716,670 showed severe symptoms and 1,584,618 showed non-severe symptoms in 2021.
• The leading Axillary Hyperhidrosis Companies working in the market include SweatBlock, Certain Dri, Duradry, Zerosweat, Allergan PLC, Dermavant Sciences Inc, Botanix Pharmaceuticals Ltd, Dermata Therapeutics Inc, Dr. August Wolff GmbH & Co KG Arzneimittel, Medytox Inc, Revance Therapeutics Inc., and others.
• Promising Axillary Hyperhidrosis Pipeline Therapies in the various stages of development include miraDry®, Sofpironium Bromide, 15%, WO3970, Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use, Botulinum Toxin Type A, and others.

Axillary Hyperhidrosis Country-based Treatment Analysis

The Axillary Hyperhidrosis treatment market report provides treatment regimens across the 7MM. It will help companies to analyze the practices followed across 7MM, the patient journey, and advances in Axillary Hyperhidrosis therapies that have the potential treatment paradigms and improve patient outcomes.

Axillary Hyperhidrosis (AH), a form of excessive sweating from armpits, is a disease that affects the social and occupational lives of many people on all continents. Axillary hyperhidrosis begins during the teenage years and equally affects men and women. Hyperhidrosis initially begins from the hands and feet during early childhood, whereas axillary hyperhidrosis often starts in adolescence.

Download the report to understand which factors are driving Axillary Hyperhidrosis Epidemiology trends @ Axillary Hyperhidrosis Epidemiology Forecast

Axillary Hyperhidrosis Epidemiology Insights

The report proffers historical and forecasted epidemiology insights that help to understand the target patient population for Axillary Hyperhidrosis. The analysis is from 2019-2032, providing insights into how the patient trends are going to shape Axillary Hyperhidrosis market dynamics. Further, the epidemiology is segmented to provide an in-depth analysis of patient pools allowing companies to understand their target patient pools.

Axillary Hyperhidrosis Epidemiology Segmentation in the 7MM

• Total Axillary Hyperhidrosis Prevalent Cases
• Axillary Hyperhidrosis Type-specific Diagnosed Prevalent Cases
• Axillary Hyperhidrosis Diagnosed Prevalent Cases
• Axillary Hyperhidrosis Age-specific Diagnosed Prevalent Cases
• Axillary Hyperhidrosis Severity-specific Diagnosed Prevalent Cases

“As per the assessments, in the US, out of the total Axillary Hyperhidrosis Diagnosed Cases in 2021, 93% accounted for primary hyperhidrosis and 7% accounted for secondary hyperhidrosis”

Axillary Hyperhidrosis Companies and Drugs

• Botanix Pharmaceuticals: Sofpironium Bromide 15%
• Dr. August Wolff GmbH & Co. KG Arzneimittel: WO3970
• Therapeutics Inc.: Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
• Northestern University: Botulinum Toxin Type A
• Anterios Inc.: ANT-1403
• Grupo de Cirurgia Vascular: Oxybutynin

To learn more about Axillary Hyperhidrosis Companies working in the treatment market, visit @ Axillary Hyperhidrosis Clinical Trials and Therapeutic Assessment

Axillary Hyperhidrosis Drugs Therapeutics Market

The therapeutic pipeline of Axillary Hyperhidrosis is very vacant with only few drugs present in the pipeline. Companies working towards the development of novel treatment therapies are expected to have considerable amount of success over the years. Key players, such as Brickell Biotech.

Axillary Hyperhidrosis Drugs Uptake

Sofpironium bromide is a small molecule, topical anticholinergic product candidate. In September 2022, Botanix Pharma submitted a New Drug Application to the FDA for approval of Sofpironium Bromide for the treatment of severe primary axillary hyperhidrosis (excessive underarmsweating). Phase III studies of Sofpironium Bromide showed very high statistical significance for the treatment of primary axillary hyperhidrosis. Initially it was being developed by Brickell Biotech. But later Botanix acquired all assets primarily related to sofpironium bromide from Brickell. In September 2020, Brickell Biotech in collaboration with Kaken, received regulatory approval in Japan to manufacture and market sofpironiumbromide gel, 5% (brand name: ECCLOCK) for the once-daily treatment of primary axillary hyperhidrosis.

Discover more about therapies set to grab major Axillary Hyperhidrosis Market Share @ Axillary Hyperhidrosis Treatment Market

Scope of the Axillary Hyperhidrosis Market Report

• Coverage- 7MM
• Study Period -2019-2032
• Forecast Period- 2023-2032
• Axillary Hyperhidrosis Companies- SweatBlock, Certain Dri, Duradry, Zerosweat, Allergan PLC, Dermavant Sciences Inc, Botanix Pharmaceuticals Ltd, Dermata Therapeutics Inc, Dr. August Wolff GmbH & Co KG Arzneimittel, Medytox Inc, Revance Therapeutics Inc., and others.
• Axillary Hyperhidrosis Pipeline Therapies- miraDry®, Sofpironium Bromide, 15%, WO3970, Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use, Botulinum Toxin Type A, and others.
• Axillary Hyperhidrosis Market Dynamics: Axillary Hyperhidrosis Market Drivers and Barriers

Note:-

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Axillary Hyperhidrosis Market Landscape.

Gain Competitive Edge in the Indication Market: Understand the current landscape of the Axillary Hyperhidrosis Market, including the competitive environment, key companies developing drugs for Axillary Hyperhidrosis, and their strategies. By analyzing Axillary Hyperhidrosis market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.

Identify Market Gaps and indication market opportunities: Analyzing epidemiological trends, country-wise patient journeys, and existing treatment practices can help in identifying gaps and opportunities within the Axillary Hyperhidrosis Market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Axillary Hyperhidrosis. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.

Strategic decision-making: Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing-reimbursement strategies, partnerships, or other strategic moves. Understanding the Axillary Hyperhidrosis market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.

Plan Roadmap to Success: Through this report, the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Axillary Hyperhidrosis Market with clarity and purpose.

Read our Blogs- Pharmaceutical and Biotech Insight, News and Blog Posts

Related Reports

Axillary Hyperhidrosis Epidemiology Forecast 2032

Axillary Hyperhidrosis Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Axillary Hyperhidrosis.

Axillary Hyperhidrosis Pipeline Insight 2023

Axillary Hyperhidrosis Pipeline Insights, 2023 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects

Discover how our tailored methodology ensures real-time evaluation of cancer therapy performance using Lead and Lag KPIs. Download our Oncology Product Assessment Case study!

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Team Lead- Marketing

Email: info@delveinsight.com

Website: https://www.delveinsight.com/